A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.

NCT03560336 · Completed

Last updated 2026-05-28

This study is testing the safety and effectiveness of the medication Saxenda® (liraglutide 3.0 mg) in adults with obesity or overweight who also have weight-related health issues, as part of routine medical care in Korea.

Status Completed The study has finished.

Type Observational

Participants 758 people

Who can join Ages 18+ · all sexes

Timeline Started 2018-07 · est. completion 2020-12

Where 28 sites · South Korea

What this study is testing ClinicalTrials.gov NCT03560336 ↗

Description as written by the study sponsor.

The purpose of this study is to collect information about the safety and effectiveness of Saxenda® in obese patients and overweight patients with obesity-related comorbidities. The participant will attend the clinic or hospital according to usual practice and receive medical care, as agreed with the study doctor. The participation is expected to be approximately for 26 weeks.

Treatments tested

Liraglutide Drug

Patients will initiate treatment with liraglutide according to the approved label in Korea. Patients will initiate 0.6 mg daily and weekly increase the dose by 0.6 mg until reaching 3.0 mg daily. Patients will then continue to stay on 3.0 mg/day (total treatment duration: 26 weeks).

Main thing measured	Incidence of adverse events (AEs) by preferred term (PT)
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity, Overweight
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03560336 ↗